Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Suguro

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Nihon Gan Chiryo Gakkai Shi|July 20, 1987
[Clinical studies of 82 spinal metastatic tumors]T Ishii, S Inoue, F Endo, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 10, 2014
Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host diseaseM Gotoh, S Yoshizawa, S Katagiri, et al.
Bone Marrow Transplantation|April 16, 2014
A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignanciesM Gotoh, S Yoshizawa, S Katagiri, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Nihon Gan Chiryo Gakkai Shi|July 20, 1987
[Clinical studies of 82 spinal metastatic tumors]T Ishii, S Inoue, F Endo, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 10, 2014
Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host diseaseM Gotoh, S Yoshizawa, S Katagiri, et al.
Bone Marrow Transplantation|April 16, 2014
A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignanciesM Gotoh, S Yoshizawa, S Katagiri, et al.
Pageof 3